Banned drugs on sale, makers face action

Several leading pharmaceutical companies face legal action after raids this week showed drugs manufactured by them continue to be available despite their having been banned by the government. Thirteen teams of officials raided some 135 pharmacists in Delhi and Rajasthan on Wednesday, and found 83 of them selling banned drugs.
Drug Controller General of India (DCGI) Dr Surinder Singh said the manufacturer is culpable, as is the retailer. "Once the drug is banned, it becomes the responsibility of the manufacturer to recall the batches of these banned drugs already in the market," Dr Singh said.
DCGI officials said the offending chemists have been issued 'Form 15', prohibiting them from disposing of the stocks of the drugs. The controller is now in the process of generating evidence against the manufacturers and distributors — a process that might take about another fortnight. After investigations are over, the controller will start proceedings for the prosecution of sellers, distributors and manufacturers, the officials said.The illegal sale of banned drugs is a non-bailable offence, and if proved, carries a punishment of three years in prison and a fine.The raids were carried out after repeated complaints at the DCGI office. Banned drugs recovered include the popular diabetes drug Rosiglitazone, the antibiotic Gatifloxicin, and Tegaserod, a medicine used to treat irritable bowel syndrome.
Rosiglitazone was banned late in 2010; the other two drugs were banned earlier this year. The government cracked down on the manufacture, sale and distribution of the drugs after they were found to have side-effects that could be harmful.

New essential drugs list finalized after eight years

India has finalized the country's all new National List of Essential Medicines (NLEM). It has 348 essential medicines, while the 2003 list had 354.Drug Controller General of India (DCGI) told TOI that 47 dugs have been deleted from the 2003 list. However, no anti-cancer or anti-HIV drugs have been deleted. They said eight new cancer drugs have been added in NLEM 2011, aggregating the tally to 30.

Carboplatin, Chlorambucil, Daunorubicin, Filgrastim, Ifosfamide, Imatinib, Mesna and Oxaliplatin are the new cancer drugs that have been included in the list.About 43 new medicines have been added in NLEM 2011, which are from 27 therapeutic categories. "The list has been finalized by an expert group that was formed by the Union health ministry on July 6, 2010.

Clinical Research Executive

Experience:0 - 3 Years
Location:Mumbai
Compensation:Rupees 2,00,000 - 3,50,000
Education:UG - B.Pharma - Pharmacy,B.Sc - Any Specialization PG - PG Diploma - Any Specialization

Role:Clinical Research Associate

Desired Candidate Profile:

Hands on experince in the field of clinical operations.
Hardworking, Adaptable.
CRO bakground will be preferable.
Science / Pharmacy background with knowledge clinical research.

Job Description
•To maintain & carry out the following responsibilities as-
•Study files & filing (CSF & ISF)
•Site Feasibility, Site assessments
•Investigator’s Meet
•Essential Documents
•Site Initiation, Monitoring & Closeout
•Trial Supply Management at Site
•IMP release, inventory check & accountability reconciliation
•Raising invoices
•SDV, CRF completion & retrieval, DCF resolution
•Preparation of Reports, Follow up reports
•Audit & to maintain & adhere quality data, Quality assurance.

Company Name:Piramal Life Sciences Ltd.
Website:http://www.piramallifesciences.com/
Telephone:22-91-30818000

HR Info of some CROs

Actimus Biosciences Pvt. Ltd-vizag" <queries@actimusbio.com>,
Asian Clinical Trials Limited-HYD <info@act-india.com>,
"Asiatic Clinical Research Pvt. Ltd-BANGLORE" <info@asiaticlinical.com>,
Avra Laboratories-HYD <info@avralab.com>,
BioAxis DNA Research Centre-SECENDERBAD <dnaresearchcentre@gmail.com>,
"Bioserve Biotechnologies (I) Pvt Ltd-HYD" <info@bioserve.com>,
celestialbiolabs-HYD <sivasankar@celestialbiolabs.com>,
celestiallabs-HYD <hr@celestiallabs.com>,
Clinigene International Limited-BANGLORE <BD@clinigeneintl.com>,
CLINiREACH Clinical Services -BANGLORE <info@clinireach.org>,
"Clintrac International Pvt. Ltd-BANGLORE" <info@clintracinternational.com>,
"Cqua Research International Inc.-SECENDERBAD" <info@cquaint.com>,
D2L Pharma Research Solutions-BANGLORE <info@d2lpharma.com>,
"Darsan Clinica Life Sciences Pvt. Ltd-HYDERBAD" <info@darsanclinica.com>,
GVK Biosciences Pvt Ltd-HYDERBAD <bdcrd@gvkbio.com>,
"Helix Research Center Pvt. Ltd-HYDERBAD" <admin@helixresearchcenter.com>,
HETERO LABS-HYD <contact@heterodrugs.com>,
Manipal Acunova-BANGLORE <bd.asia@ecronacunova.com>,
"Merit Medical & Allied Sciences Pvt Ltd (SMO)-CHENNAI" <info@meritclinicalresearch.in>,
Omnicare Clinical Research-BANGLORE <Investigators@omnicarecr.com>,
"Quintiles Technologies Pvt. Ltd.-BANGLORE" <clinical.info@quintiles.com>,
Ranbaxy Laboratories Limited-GURGOAN <ramesh.adige@ranbaxy.com>,
RANBAXY- CONSULTANT <shruti.wadhwa@abcconsultants.net>,
Reametrix -BANGLORE <info@reametrix.com>,
Dr Reddy's Laboratories Limited-HYDERBAD <webmaster@ddreddys.com>,
"DR.REDDY'S LABS-HYD" <corporatehr@drreddys.com>,
Reliance Clinical Research Services- NAVI MUMBAI <ClinicalResearch.Enquiry@relclin.com>,
Rhenium Clinical Research Pvt Ltd-BANGLORE <info@rheniumresearch.com>,
SIPRA LABS <sipra@sipralabs.com>,
VIMTA LABS <vimtahq@vimta.com>,
vimtas labs hyd <mdo@vimta.com>,